Compare Bank of New York Mellon Corp (BNY) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of New York Mellon Corp vs Twist Bioscience Corp — how do they compare? Bank of New York Mellon Corp trades at $159.38 (market cap $106.05B), while Twist Bioscience Corp trades at $93.02 (market cap $5.77B). The key difference: Bank of New York Mellon Corp is far larger — about 18.4× Twist Bioscience Corp's market cap, and Bank of New York Mellon Corp pays a 1.37% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| BNY | TWST | |
|---|---|---|
Market Cap | $106.05B | $5.77B |
Sector | Financials | Health |
52-Week High | $154.50 | $102.88 |
52-Week Low | $95.16 | $24.16 |
Dividend Yield | 1.37% | — |
Enterprise Value | — | $5.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNY trades at $151.27, down 0.43% on the day, with a bullish technical signal supported by moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Revenue growth has been steady, rising from $16.0B in 2022 to $19.8B in 2025, while net income margin improved to 29.21%. Analyst consensus is mixed with 38% buy ratings but a $156 price target suggesting modest upside. Recent news highlights strong fee income expectations and a planned 19% dividend increase.
BNY demonstrates solid fundamental strength with improving profitability and consistent earnings beats. The stock offers potential upside to analyst targets and dividend growth, but faces risks from high investing cash outflows and competitive pressures. Current valuation metrics appear reasonable relative to historical performance, though investors should monitor Q2 earnings results for confirmation of growth trajectory.
TWST trades at $90.35, down 0.31% on the day, with a bullish technical signal supported by moving averages and oversold RSI levels near key support at $89. Revenue growth remains strong, reaching $376.57M in 2025, though the company continues to report net losses. Recent news highlights AI-driven drug discovery collaborations and insider selling activity, while analyst consensus leans bullish with a $91.63 price target.
The stock offers growth exposure to synthetic biology and AI-enabled therapeutics, but carries significant risk due to persistent negative cash flow and profitability challenges. Investor sentiment is cautiously optimistic, balancing innovation potential against financial sustainability concerns in a competitive biotech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of New York Mellon Corp
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
